Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/08/2020 07/09/2020 07/10/2020 07/13/2020 07/14/2020 Date
160.42(c) 159.03(c) 162.25(c) 152.74(c) 157.23 Last
851 796 480 065 748 720 667 921 769 182 Volume
+0.26% -0.87% +2.02% -5.86% +2.94% Change
More quotes
Financials (USD)
Sales 2020 489 M - -
Net income 2020 -720 M - -
Net cash position 2020 1 040 M - -
P/E ratio 2020 -23,9x
Yield 2020 -
Sales 2021 854 M - -
Net income 2021 -523 M - -
Net cash position 2021 1 333 M - -
P/E ratio 2021 -34,4x
Yield 2021 -
Capitalization 17 620 M 17 620 M -
EV / Sales 2020 33,9x
EV / Sales 2021 19,1x
Nbr of Employees 1 323
Free-Float 99,2%
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
08:23aALNYLAM PHARMACEUTICALS : announces that the United Kingdom's MHRA Grants Early ..
AQ
08:09aOat-Milk Company Oatly Draws Investment From Blackstone-Led Group -- Update
DJ
12:45aOat-Milk Company Oatly Draws Investment From Blackstone-Led Group Including O..
DJ
07/13ALNYLAM PHARMACEUTICALS : Announces that the United Kingdom's MHRA Grants Early ..
BU
07/08ALNYLAM PHARMACEUTICALS : and Taiba Group Partner to Commercialize RNAi Therapeu..
BU
06/30ALNYLAM PHARMACEUTICALS : Reports New 12-Month Interim Data From the ENVISION Ph..
BU
06/19ALNYLAM PHARMACEUTICALS : to Host Seventh Annual 'RNAi Roundtable' Webcast Serie..
AQ
06/18ALNYLAM PHARMACEUTICALS : to Host Seventh Annual “RNAi Roundtable” W..
BU
06/17ALNYLAM PHARMACEUTICALS : to Webcast Presentation at Bank of America Securities ..
BU
06/10ALNYLAM PHARMACEUTICALS : Announces Publication of ENVISION Phase 3 Study Result..
BU
06/08ALNYLAM PHARMACEUTICALS : BIO - Targeting 'Undruggable' Diseases
AQ
06/07ALNYLAM PHARMACEUTICALS : Presents Positive Phase 3 Results from ILLUMINATE-A St..
BU
06/02ALNYLAM PHARMACEUTICALS : Announces Recipients of Second Annual Advocacy for Imp..
BU
06/01ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing Full Results fro..
BU
05/26ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming June Investor Con..
BU
More news
News in other languages on ALNYLAM PHARMACEUTICALS, I
08:23aALNYLAM PHARMACEUTICALS : announces that the United Kingdom's MHRA Grants Early ..
08:09aOat-Milk Company Oatly Draws Investment From Blackstone-Led Group -- Update
12:45aOat-Milk Company Oatly Draws Investment From Blackstone-Led Group Including O..
07/13ALNYLAM PHARMACEUTICALS : Announces that the United Kingdom's MHRA Grants Early ..
07/09ALNYLAM PHARMACEUTICALS : und Taiba Group kooperieren beim Vertrieb von RNAi-The..
More news
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | MarketScreener
Technical analysis trends ALNYLAM PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 154,43 $
Last Close Price 152,74 $
Spread / Highest target 32,3%
Spread / Average Target 1,11%
Spread / Lowest Target -51,6%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Jeffrey Poulton Chief Financial & Accounting Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.32.62%17 620
LONZA GROUP53.57%42 797
SEATTLE GENETICS, INC.47.54%29 181
MODERNA, INC.266.97%27 910
IQVIA HOLDINGS INC.-8.56%26 979
INCYTE CORPORATION15.16%21 859